In 1980, Ludwig and colleagues described the histologic features of a newly identified chronic liver condition referred to as nonalcoholic steatohepatitis (NASH) and noted that the majority of the ...

A recent review highlights a promising therapeutic target for metabolic dysfunction–associated fatty liver disease (MAFLD) ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. Right now, patients with obesity and cirrhosis ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

Obesity worsens chronic liver disease, but novel medications and bariatric surgery offer new options. Learn more about effective weight-loss strategies.

A new study suggests Vitamin B3 may help reverse fatty liver disease by targeting microRNA-93, which drives fat buildup. By ...

When most people think about liver disease, they think about alcohol or hepatitis. What many don’t realize is that the most ...

After adjusting for alcohol underreporting, prevalence doubled ...

What Is Metabolic Dysfunction-Associated Steatohepatitis? Metabolic dysfunction-associated steatohepatitis, or MASH, is a form of liver disease. MASH occurs when fat accumulates in liver cells. Plenty ...

Intestinal failure–associated liver disease (IFALD) is a major concern in the management of pediatric intestinal failure, representing a leading cause of ...